<DOC>
	<DOCNO>NCT01934543</DOCNO>
	<brief_summary>The overaccumulation apolipoprotein ( apo ) B-48-containing lipoproteins intestinal origin observe patient insulin-resistance thought attributable elevate intestinal production reduce clearance lipoprotein . Substantial evidence exists indicate elevate plasma level lipoproteins associate increase cardiovascular disease ( CVD ) risk . Therefore , reduction atherogenic plasma TRL level intestinal origin appear crucial improve CVD risk associate insulin-resistance . In regard , evidence clinical recommendation replace dietary saturate fatty acid ( SFAs ) n-6 polyunsaturated fatty acid ( PUFAs ) reduce CVD risk general population . Although beneficial impact n-6 PUFAs CVD risk relate primarily favorable change plasma LDL-cholesterol level , recent data suggest chronic n-6 PUFA consumption may also exert beneficial effect CVD risk reduce postprandial lipemia . The impact substitute SFAs n-6 PUFAs postprandial lipid response may even great significance dyslipidemic patient insulin-resistance among intestinal triglyceride-rich lipoprotein ( TRLs ) represent large proportion atherogenic lipoprotein . The general objective propose research investigate dietary n-6 PUFAs place SFAs modify intestinal lipoprotein metabolism men dyslipidemia associate insulin-resistance . The investigator hypothesize intestinal secretion apoB-48-containing lipoprotein low follow diet rich n-6 PUFAs consume diet rich SFAs . The investigator also hypothesize substitution SFAs n-6 PUFAs associate significant alteration expression key gene protein involve intestinal lipoprotein metabolism .</brief_summary>
	<brief_title>Effects Polyunsaturated Fatty Acids Intestinal Lipid Metabolism Insulin-resistant Men</brief_title>
	<detailed_description />
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<criteria>Men age 1860 year Waist circumference &gt; 102 cm HDLcholesterol &lt; 1.1 mmol/L Triglycerides &gt; 1.7 mmol/L Fasting blood glucose &gt; 6.1 mmol/L Normal blood pressure ( &lt; 130/85 ) Women Men &lt; 18 &gt; 60 year Smokers ( &gt; 1 cigarette/day ) Body weight variation &gt; 10 % last 6 month prior study baseline Subjects previous history cardiovascular disease Subjects type 2 diabetes Subjects monogenic dyslipidemia Subjects hypertension medication medication know affect lipoprotein metabolism integrity gastrointestinal mucosa Subjects endocrine gastrointestinal disorder History alcohol drug abuse within past 2 year Subjects situation condition , opinion investigator , may interfere optimal participation study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>